Cyltezo®, first and only FDA-approved Interchangeable biosimilar to Humira®, now commercially available in the U.S.
Cyltezo®, first and only FDA-approved Interchangeable biosimilar to Humira®, now commercially available in the U.S.
Search
Schizophrenia in real life: Stories of resilience and hope
Discover the reality of life with schizophrenia through the stories of four people who are breaking down the stigma of living with a serious mental illness.
Low-WAC interchangeable biosimilar is now available
Adalimumab-adbm, our interchangeable biosimilar to Humira, now available at a low wholesale acquisition cost.
Boehringer Ingelheim and Tsinghua University Team up to Develop Novel Treatment Approaches that Rally the Immune System Against Infectious Diseases
Boehringer Ingelheim and Tsinghua University Team up to Develop Novel Treatment Approaches that Rally the Immune System Against Infectious Diseases
FDA approves additional formulation of biosimilar
US FDA approves additional formulation of Cyltezo® (adalimumab-adbm). See Important Safety Information including Boxed Warning, Prescribing Information, Medication Guide and Instructions for Use.
Depression
Depression
Saving Stroke Patients around the world
Suffering a stroke is one of the most devastating medical emergencies that can happen to a person. Over 15 million people worldwide suffer a stroke every year.
Borderline Personality Disorder
Borderline Personality Disorder
Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company Statement on the ADA Request for Independent Review of Incretin-Based Therapies
Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company Statement on the ADA Request for Independent Review of Incretin-Based Therapies
Evolving the Unwearable Collection
Boehringer Ingelheim will partner with the Fashion Institute of Technology in New York to introduce a fifth design as part of The Unwearable Collection™
Innovation in Medicinal Chemistry: Unlocking Unsolved Diseases
Innovation in Medicinal Chemistry: Unlocking Unsolved Diseases
Science Stories
Science Stories
Trends & Insights
News
Animal Health
Companion Animals, Horse Pets and Equines
First half 2019: High levels of investment in R&D and robust organic growth
First half 2019: High levels of investment in R&D and robust organic growth
Vampire Bats & Rabies: A Potential New Threat | Boehringer Ingelheim US
Read more on the emerging threat of rabid vampire bats in the Southern US. Helping prevent this disease preserves the lives of livestock worldwide.
Skin and Inflammatory Diseases
skin diseases
First half of 2023: Boehringer Ingelheim sees strong growth and expansion in key therapy areas
Currency-adjusted net sales rose by 9.7 percent to 13.5 billion USD.
Focus on Alliance Management
Focus on Alliance Management
Partnering for Innovative Pet Therapeutics
Partnering for Innovative Pet Therapeutics
Biosimilars
: A biosimilar is a version of a biologic medication that is made by a different company than the one that invented it, with no clinically meaningful differences in terms of safety, potency and purity.
Schizophrenia
Schizophrenia
Making Toys for Shelter Animals | Boehringer Ingelheim US
Find out how nearly 400 Boehringer Ingelheim employees came together to make toys out of donated t-shirts for animals living in shelters across the USA.
Research & Development Video | BI Careers
Prof. Eric Haaksma speaks about his career and the Boehringer Ingelheim mission to transform lives for generations.
Let’s find CKD
More than 35 million Americas are living with chronic kidney disease (CKD), and most of them don’t know it. Early diagnosis of CKD needs to be a national priority.